Close Menu

UC Riverside

The Los Angeles Times reports on a peptide that may treat huanglongbing, also known as citrus greening disease.

The $10 million initiative will include scientists from the University of California's campuses, as well as from governmental and nongovernmental organizations.

In PNAS this week: blood plasma lipidome analysis of Ebola patients, genome organization of the malaria-causing parasite, and more.

In PNAS this week: drug resistance evolution in Candida in a cystic fibrosis patient, point mutation in cotton bollworm allows it to persist in "Bt" crops, and more.

In Cell this week: structural variant profiles for metastatic prostate cancer; approach for visualizing mRNA, lncRNA transcription; and more.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.

The group will study the potential risks and benefits of using CRISPR/Cas9 to develop gene drive systems for control and manipulation of mosquito populations.

Unlike existing versions, CLARK-S allows mismatches between sample reads and reference databases, enabling it to map a larger proportion of input sequences.

NEW YORK (GenomeWeb) – A researcher at the University of California, Riverside has received a five-year, $1.8 million grant to produce fine-scale recombination rate maps for the African malaria mosquito in research aimed at preventing transmission of the disease.

NEW YORK (GenomeWeb News) – Research partners at the University of Washington and the University of California, Riverside have netted $2 million in funding from the National Institutes of Health to study the genome of the Plasmodium parasite, which causes malaria, UC Riverside said on We

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.